The newly listed medical firm saw its shares settle at HK$8.80 after opening 35.1 percent under the HK$15.42 offer, with the session spanning HK$8.41 to HK$10.90 on 12.15 million shares traded.
The newly listed medical firm saw its shares settle at HK$8.80 after opening 35.1 percent under the HK$15.42 offer, with the session spanning HK$8.41 to HK$10.90 on 12.15 million shares traded.

A HK$662 loss per 100-share board lot greeted MEDCAPTAIN (02041.HK) subscribers on the company's first day of trading, as the stock settled at HK$8.80 — a 42.9 percent plunge from the HK$15.42 listing price.
The newly listed company's shares opened at HK$10, already 35.1 percent below the offer price, and never recovered during the session. The stock peaked at HK$10.90 and bottomed at HK$8.41 before settling at the close.
Volume reached 12.15 million shares, generating turnover of HK$128.71 million. The debut-day collapse follows Morgan Stanley cutting its mainland China and Hong Kong stock index targets across the board, lowering the Hang Seng Index target to 26,550.
The poor first-day performance points to weak demand for new listings in Hong Kong's current market environment. Investors who subscribed at the HK$15.42 offer price face an immediate paper loss of 42.9 percent, and the stock's trajectory in coming sessions will test whether the decline is company-specific or part of broader IPO market weakness.
The Hang Seng Index's recent softness, reflected in Morgan Stanley's target cut, has dampened appetite for new equity offerings across the exchange. MEDCAPTAIN's next trading sessions will show whether the stock stabilizes near its debut close or extends losses, a key test for issuers planning Hong Kong listings in the current climate.
This article is for informational purposes only and does not constitute investment advice.